Commenting today on the Centers for Medicare & Medicaid Services’ proposed rule for the inpatient rehabilitation facility prospective payment system for fiscal year 2020, AHA said it generally supports the reforms to update the payment system, but expressed concern with the substantial redistribution of cases under the payment model proposed for FY 2020. The comment letter raises concerns regarding the FY 2020 case-mix system reforms finalized in last year’s rulemaking, as well as proposed changes to quality outcomes reporting and patient assessments. “[W]e remain concerned that these new policies are, in part, based on unreliable data and that the proposed rule lacks adequate detail and transparency,” AHA wrote. “We also are concerned that the proposed rule lacks the patient-level and cost data needed to replicate the model for the purpose of evaluating its impact to consider whether alternatives would be warranted. These issues deserve further discussion and transparency in the final rule to allow the field to best prepare for the changes and serve their patients.”

Related News Articles

Headline
President Trump today released his discretionary spending budget blueprint for fiscal year 2026. The “skinny budget” request, which includes top line…
Headline
The AHA May 1 expressed concerns (LINK) to the Centers for Medicare & Medicaid Services about the payment process established under the Medicare…
Headline
The Supreme Court April 29 ruled 7-2 in favor of the Department of Health and Human Services in a case that challenged how HHS applied Congress’ formula for…
Headline
The House Energy and Commerce Committee held a markup April 29 where it advanced the AHA-supported SUPPORT Act (H.R. 2483). The legislation would reauthorize…
Headline
Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy, M.D., R-La., today released a report detailing findings from an investigation…
Headline
The AHA April 18 filed friend-of-the-court briefs in three cases in support of Louisiana's 340B contract pharmacy law that prohibits drug companies from…